As a leading provider of cancer screening and genomic-based diagnostic tests, we are relentless in our pursuit to find the right science and technology for every challenge. Our approach is defined not only by our rigorous process, but also by our willingness to explore any angle that leads to the best answer. We combine resourcefulness, expertise, and an open mind to develop life-changing innovations, rooted in the needs of patients, clinicians, and families.
Precision Oncology
The Oncotype IQ® portfolio of genomic tests are aimed at helping individual cancer patients and their clinicians uncover underlying cancer biology to guide treatment decisions and help to avoid over- and undertreatment.
Screening
Our leading screening brand, Cologuard®, is the first and only FDA-approved stool DNA test for colorectal cancer and is included in the American Cancer Society’s colon cancer screening guidelines. The Cologuard test is available only in the United States.
The Pipeline
Through our pipeline efforts, we want to change the way cancer is diagnosed and treated by finding it earlier and providing better information to patients and clinicians at every step of the cancer journey.
